BioVie Stock Plummets 46% After SEC Clearance as Neurology and Liver Pipeline Advances

Introduction

BioVie Inc. (NASDAQ: BIVI) is a clinical-stage biotechnology company focused on developing therapies for neurological and neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, and the neurological effects of long COVID, as well as advanced liver disease. The company’s lead molecule, bezisterim (NE3107), targets tumor necrosis factor-alpha (TNF-α) to address neuroinflammation and insulin resistance. Additionally, BioVie is developing BIV-201 (continuous-infusion terlipressin) for the treatment of ascites associated with liver cirrhosis.

Corporate Structure

Founded in 2013 and headquartered in Carson City, Nevada, BioVie operates as a public company with approximately 11 to 50 employees. The board of directors was expanded on August 5, 2025, with the appointments of Amy Chappell, M.D., FAAN, and Kameel Farag, who bring expertise in neuroscience drug development and biotechnology finance. BioVie’s management team possesses clinical research, regulatory, and commercial experience in both neurology and liver disease.

Neurodegenerative therapies by Milad Fakurian

Developments and News

On August 7, 2025, the U.S. Securities and Exchange Commission declared effective BioVie’s Form S-1 registration, allowing for public offering activities. That same day, the company filed Form 8-A12B to register warrants to purchase shares of Class A common stock on the Nasdaq Stock Market.

At the 2nd World Conference on Aging and Gerontology (WCAG-2025), BioVie presented data suggesting bezisterim may influence epigenetic markers associated with age-related changes in Alzheimer’s and other neurodegenerative diseases. On July 15, 2025, a poster describing the Phase 2 SUNRISE-PD trial of bezisterim in early Parkinson’s disease received an award at the ATMRD 2025 Congress. Additionally, a webinar replay of the ADDRESS-LC trial in long COVID was made available on June 30, 2025.

Financial and Strategic Analysis

On August 8, 2025, BIVI shares closed at $1.5650, down 46.22% from the prior trading day’s close of $2.91, on a volume of 431,362 shares. The company’s market capitalization was approximately $5.4 million, with 1.86 million shares outstanding. Over the past 52 weeks, the stock traded between a high of $75.00 on October 21, 2024, and a low of $2.86 on August 7, 2025.

For the trailing twelve months, BioVie reported negative EBITDA of $18.7 million and an EPS of –$21.14, resulting in a P/E ratio of –0.14. The forward P/E multiple is reported at 20.79, based on projected earnings. Return on equity was reported at 95.05%. These metrics are reflective of ongoing research and development investments in bezisterim and BIV-201.

Strategically, BioVie is seeking partners to support a Phase 3 trial of BIV-201 in decompensated cirrhosis with ascites. The company’s neurology pipeline continues to focus on inflammation modulation and enhancing energy transfer in the brain, which are key components of its Alzheimer’s, Parkinson’s, and long COVID programs.

Market Position and Industry Context

As a small-cap biotech firm, BioVie competes in the sectors of neurodegenerative and liver disease therapeutics. Its focus on TNF-α inhibition and insulin sensitization in the brain marks a distinct approach compared to traditional symptomatic treatments. In advanced liver disease, there are currently no approved therapies for ascites beyond fluid management, positioning BIV-201 to potentially meet an unmet medical need. Regulatory milestones and clinical trial outcomes will be pivotal for BioVie’s ability to secure partnerships, raise capital, and advance toward commercialization.

tl;dr

On August 7, 2025, the SEC approved BioVie’s S-1 registration and Form 8-A12B listing of warrants. The stock fell 46.22% to $1.5650 on August 8, 2025, with a shift from private to public financing. BioVie presented findings at WCAG-2025 and ATMRD 2025, with a long COVID trial webinar replay released on June 30, 2025. The company aims to initiate a Phase 3 trial of BIV-201 for cirrhosis-related ascites and continues Phase 2 studies of bezisterim in Alzheimer’s and Parkinson’s diseases.